T.Man Pharmaceutical PCL (BKK:TMAN)

Market Cap	5.08B -1.6%
Revenue (ttm)	2.53B +13.5%
Net Income	523.07M +16.1%
EPS	1.31 -0.4%
Shares Out	400.00M
PE Ratio	9.71
Forward PE	9.77
Dividend	0.32 (2.54%)
Ex-Dividend Date	May 8, 2026

Volume	63,500
Average Volume	393,819
Open	12.70
Previous Close	12.70
Day's Range	12.70 - 12.90
52-Week Range	9.90 - 13.60
Beta	n/a
RSI	55.24
Earnings Date	May 14, 2026

About T.Man Pharmaceutical PCL

T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties’ Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 944
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: TMAN

Financial Performance

In 2025, T.Man Pharmaceutical PCL's revenue was 2.53 billion, an increase of 13.48% compared to the previous year's 2.23 billion. Earnings were 523.07 million, an increase of 16.06%.